-
Clover Biopharmaceuticals’ SCB-2019 COVID-19 Vaccine Shows Strong Immune Response in Third Shot Study
•
China-based Clover Biopharmaceuticals Ltd (HKG: 2197) has published clinical data for its COVID-19 vaccine candidate SCB-2019 (CpG 1018/Alum) as a third shot. The double-blind, randomized, controlled study demonstrated significant increases in neutralizing antibodies against Omicron variants BA.2 and BA.1. Clinical Study ResultsThe study enrolled 3,755 subjects in Brazil, the Philippines,…
-
Harbour BioMed Receives FDA Approval for HBM7008 Clinical Trials
•
China-based Harbour BioMed (HKG: 2142) has announced receiving clinical trial approval from the US FDA for its bispecific antibody HBM7008. The drug, which targets the tumor antigen B7H4 and T cell co-stimulatory molecule 4-1BB, was first dosed in Phase I clinical trials in Australia in May and obtained clinical approval…
-
Joysbio Develops Rapid Test for SARS-CoV-2 Omicron Subvariants BA.4 and BA.5
•
China-based Joysbio (Tianjin) Biotechnology Co., Ltd. has developed a rapid test to diagnose the latest SARS-CoV-2 omicron subvariants BA.4 and BA.5. The Joysbio Coronavirus Antigen Rapid Test Kit, suitable for self-testing and requiring no professional support, can effectively detect these subvariants and has been certified by the Polish Centre for…
-
Antengene and BeiGene Collaborate on Selinexor and Tislelizumab Combination Trial for Lymphoma
•
China-based Antengene Corporation Ltd (HKG: 6996) has announced a clinical trial collaboration with BeiGene Inc. (Nasdaq: BGNE) to evaluate the combination of Antengene’s selinexor (trade name: Xpovio) with BeiGene’s anti-PD-1 drug tislelizumab (Baizean). The open-label, multi-center Phase I/II trial aims to explore this combination as a potential treatment for patients…
-
Sino Biopharmaceutical’s TQ-B3101 Accepted by NMPA for ROS1+ NSCLC Treatment
•
China-based Sino Biopharmaceutical Ltd (HKG: 1177) has announced that the National Medical Products Administration (NMPA) has accepted the market filing for its Category 1 product TQ-B3101 for the treatment of ROS1-positive non-small cell lung cancer (NSCLC). Drug Mechanism and EfficacyTQ-B3101 is a small molecule inhibitor targeting tyrosine kinase ROS1/ALK/c-Met. It…
-
Sanyou Biopharmaceuticals and Dragon Sail Form Strategic Partnership for Global Biopharma Services
•
China-based Sanyou Biopharmaceuticals Co., Ltd has entered into a long-term strategic partnership with compatriot firm Dragon Sail Pharmaceutical. The collaboration aims to provide integrated and modular solutions covering biological drug research and development (R&D), Contract Development and Manufacturing Organization (CDMO) services, and commercial-scale production for the global biopharmaceutical industry. Partnership…
-
Westlake Therapeutics Secures RMB 100 Million in Series A+ Funding for Red Cell Therapy Pipeline
•
Hangzhou-based cell therapy firm Westlake Therapeutics, founded in 2019, has successfully raised over RMB 100 million (USD 14.95 million) in a Series A+ financing round. The funding was led by EFung Capital, with participation from Ao Peng Investment, Hangzhou Westlake Science Innovation Equity Investment, and Westlake Innovation (Hangzhou) Equity Investment.…
-
PhenoVision Bio Secures Angel Funding for Spatial Multi-Omics Technology Platform
•
Beijing-based PhenoVision Biotech, a one-stop spatial multi-omics solution provider, has reportedly secured “tens of millions” of renminbi in an angel financing round led exclusively by SIP Oriza Seed Fund. The proceeds will be dedicated to constructing a spatial multi-omics technology platform and advancing the development of clinical products. Funding and…
-
GSK Launches Nucala in China for Eosinophilic Granulomatosis with Polyangiitis
•
UK pharmaceutical giant GlaxoSmithKline (GSK, LON: GSK, NYSE: GSK) has announced the official market launch in China of its monoclonal antibody Nucala (mepolizumab) for the treatment of adult eosinophilic granulomatosis with polyangiitis (EGPA). This move expands the drug’s availability to patients in China, offering a new therapeutic option for this…
-
Genor Biopharma and Abogen Biosciences Collaborate on Cancer mRNA Therapies
•
China’s Genor Biopharma Co., Ltd (HKG: 6998) has entered into a co-development agreement with compatriot firm Abogen Biosciences Co., Ltd, a Suzhou-based mRNA drug developer. The collaboration aims to develop mRNA medicines against cancer by integrating Genor’s biologic antibody development platform with Abogen’s mRNA technology platform. Collaboration DetailsThe partnership combines…
-
Sunshine Guojian Pharmaceutical Signs Licensing Deal for Cipterbin ADC Development
•
China-based Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd, a subsidiary of 3SBio Inc. (HKG: 1530), has announced the signing of a licensing agreement with compatriot firm Xiling Lab’s wholly-owned unit Chengdu Kelingyuan Pharmaceutical Co., Ltd. The agreement grants Chengdu Kelingyuan global development and commercialization rights to the anti-HER2 monoclonal antibody (mAb)…
-
Takeda Pharmaceutical’s Teduglutide Filed for Marketing Approval in China
•
The Center for Drug Evaluation (CDE) website in China indicates that Japan-based Takeda Pharmaceutical Co., Ltd’s best-in-class injectable therapy teduglutide has been filed for marketing approval. This marks a significant step for the drug in the Chinese market. Drug BackgroundTeduglutide, the first and only natural glucagon-like peptide-2 (GLP-2) drug approved…
-
Guangzhou Baiyunshan Halts Spinning-off of Guangzhou Pharmaceutical Amid HK Capital Shifts
•
China-based Guangzhou Baiyunshan Pharmaceutical Co., Ltd (SHA: 600332) has announced the suspension of the spinning-off of its subsidiary Guangzhou Pharmaceutical Co., Ltd. This decision comes after considering the reply expiration date from the China Securities Regulatory Commission (CSRC) and changes in the Hong Kong capital market. Regulatory TimelineGuangzhou Pharma first…
-
Frontier Biotech’s Albuvirtide Shows Promising HIV Treatment Results in Phase III Trial
•
China-based Frontier Biotechnologies Inc. (SHA: 688221) has released Phase III trial data for albuvirtide, China’s first homegrown innovative HIV therapy. The non-inferiority “TALENT” study assessed the performance of the long-acting HIV fusion inhibitor albuvirtide in combination with Kaletra (ritonavir-boosted lopinavir) in 418 Chinese patients with HIV-1 over 48 weeks. The…
-
Organon’s China Head Shi Wang Departs to Lead Sanofi Greater China
•
Women’s health specialist Organon (NYSE: OGN) announced the departure of its former China unit head Shi Wang on July 31, with his successor undisclosed. Meanwhile, French major Sanofi revealed that Shi Wang will take the helm of Sanofi Greater China as president and general medicine head as of August 1,…
-
Antengene Receives Australian TGA Approval for ATG-018 Clinical Trial
•
China-based biopharma Antengene Corporation (HKG: 6996) has announced receiving approval from the Therapeutic Goods Administration (TGA) of Australia to initiate a Phase I clinical trial for its candidate ATG-018. The trial, named ATRIUM, will evaluate the drug in patients with advanced solid tumors and hematological malignancies. Drug MechanismATG-018 is an…
-
Helixon Secures RMB 500 Million in Series A Round to Advance AI-Driven Drug Development
•
Beijing-based Helixon, an artificial intelligence (AI)-empowered pharmaceutical company, has reportedly secured RMB 500 million (USD 74.5 million) in a Series A financing round. The funding was led by 5Y Capital, with participation from Gaorong Capital, Neumann Capital, Xiang He Capital, GL Ventures, and Qingzhi Capital. The proceeds will be utilized…
-
Jumbo Drug Bank’s JDB153 Enters Phase I Trial for Advanced Solid Tumors
•
Data from Fineline Cube indicates that JDB153, a potential first-in-class (FIC) small-molecule inhibitor targeting Mnk and VEGFR developed by China-based biotech Jumbo Drug Bank, entered a Phase I clinical study on June 13, 2022. The trial, initiated one week after receiving approval from the National Medical Products Administration (NMPA), is…
